45 results on '"Lupatsch, Judith E."'
Search Results
2. Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer
- Author
-
Mehra, Tarun; https://orcid.org/0009-0005-8429-5110, Lupatsch, Judith E, Kössler, Thibaud, Dedes, Konstantin; https://orcid.org/0000-0002-8741-9319, Siebenhüner, Alexander Reinhard, von Moos, Roger, Wicki, Andreas; https://orcid.org/0000-0002-2924-8080, Schwenkglenks, Matthias E; https://orcid.org/0000-0001-7217-1173, Mehra, Tarun; https://orcid.org/0009-0005-8429-5110, Lupatsch, Judith E, Kössler, Thibaud, Dedes, Konstantin; https://orcid.org/0000-0002-8741-9319, Siebenhüner, Alexander Reinhard, von Moos, Roger, Wicki, Andreas; https://orcid.org/0000-0002-2924-8080, and Schwenkglenks, Matthias E; https://orcid.org/0000-0001-7217-1173
- Abstract
OBJECTIVE To assess the cost-effectiveness and budget impact of olaparib as a maintenance therapy in platinum-responsive, metastatic pancreatic cancer patients harboring a germline BRCA1/2 mutation, using the Swiss context as a model. METHODS Based on data from the POLO trial, published literature and local cost data, we developed a partitioned survival model of olaparib maintenance including full costs for BRCA1/2 germline testing compared to FOLFIRI maintenance chemotherapy and watch-and-wait. We calculated the incremental cost-effectiveness ratio (ICER) for the base case and several scenario analyses and estimated 5-year budget impact. RESULTS Comparing olaparib with watch-and wait and maintenance chemotherapy resulted in incremental cost-effectiveness ratios of CHF 2,711,716 and CHF 2,217,083 per QALY gained, respectively. The 5-year costs for the olaparib strategy in Switzerland would be CHF 22.4 million, of which CHF 11.4 million would be accounted for by germline BRCA1/2 screening of the potentially eligible population. This would amount to a budget impact of CHF 15.4 million (USD 16.9 million) versus watch-and-wait. CONCLUSIONS Olaparib is not a cost-effective maintenance treatment option. Companion diagnostics are an equally important cost driver as the drug itself.
- Published
- 2024
3. Space–time clustering of childhood cancers : a systematic review and pooled analysis
- Author
-
Kreis, Christian, Doessegger, Eliane, Lupatsch, Judith E., and Spycher, Ben D.
- Published
- 2019
4. A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC)
- Author
-
Panje, Cedric M., Dedes, Konstantin J., Matter-Walstra, Klazien, Schwenkglenks, Matthias, Gautschi, Oliver, Siano, Marco, Aebersold, Daniel M., Plasswilm, Ludwig, and Lupatsch, Judith E.
- Published
- 2018
- Full Text
- View/download PDF
5. Childhood brain tumours, early infections and immune stimulation: A pooled analysis of the ESCALE and ESTELLE case-control studies (SFCE, France)
- Author
-
Lupatsch, Judith E., Bailey, Helen D., Lacour, Brigitte, Dufour, Christelle, Bertozzi, Anne-Isabelle, Leblond, Pierre, Faure-Conter, Cécile, Pellier, Isabelle, Freycon, Claire, Doz, François, Puget, Stéphanie, Ducassou, Stéphane, Orsi, Laurent, and Clavel, Jacqueline
- Published
- 2018
- Full Text
- View/download PDF
6. Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.
- Author
-
Mehra, Tarun, Lupatsch, Judith E., Kössler, Thibaud, Dedes, Konstantin, Siebenhüner, Alexander Reinhard, von Moos, Roger, Wicki, Andreas, and Schwenkglenks, Matthias E.
- Subjects
- *
PANCREATIC cancer , *OLAPARIB , *METASTASIS , *COMPANION diagnostics , *BUDGET - Abstract
Objective: To assess the cost-effectiveness and budget impact of olaparib as a maintenance therapy in platinum-responsive, metastatic pancreatic cancer patients harboring a germline BRCA1/2 mutation, using the Swiss context as a model. Methods: Based on data from the POLO trial, published literature and local cost data, we developed a partitioned survival model of olaparib maintenance including full costs for BRCA1/2 germline testing compared to FOLFIRI maintenance chemotherapy and watch-and-wait. We calculated the incremental cost-effectiveness ratio (ICER) for the base case and several scenario analyses and estimated 5-year budget impact. Results: Comparing olaparib with watch-and wait and maintenance chemotherapy resulted in incremental cost-effectiveness ratios of CHF 2,711,716 and CHF 2,217,083 per QALY gained, respectively. The 5-year costs for the olaparib strategy in Switzerland would be CHF 22.4 million, of which CHF 11.4 million would be accounted for by germline BRCA1/2 screening of the potentially eligible population. This would amount to a budget impact of CHF 15.4 million (USD 16.9 million) versus watch-and-wait. Conclusions: Olaparib is not a cost-effective maintenance treatment option. Companion diagnostics are an equally important cost driver as the drug itself. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Cost-effectiveness of pembrolizumab as an adjuvant treatment of renal cell carcinoma post-nephrectomy in Switzerland.
- Author
-
Schur, Nadine, Favre-Bulle, Andrea, Flori, Michael, Xiao, Ying, and Lupatsch, Judith E.
- Subjects
RENAL cell carcinoma ,SWISS franc ,RENAL cancer ,OVERALL survival ,MARKOV processes - Abstract
Aims: Pembrolizumab has demonstrated significantly prolonged disease-free survival and overall survival (OS) among adult patients post-nephrectomy who have an intermediate-high risk, high-risk, or M1 stage with no evidence of disease (M1 NED) renal cell carcinoma (RCC) with clear cell component. The aim of this study was to evaluate the cost-effectiveness of pembrolizumab for patients with RCC post-nephrectomy versus observation in Switzerland. Materials and methods: A previously published Markov model was adapted for the Swiss setting to estimate the cost-effectiveness of adjuvant pembrolizumab versus observation from the Swiss statutory health insurance perspective. Transition probabilities between model states were estimated using survival curves from KEYNOTE-564 (data cut-off: 14 June 2021). Outcomes included costs (2022 Swiss francs [CHF]), quality-adjusted life-years (QALYs), and life-years (LYs), measured over a lifetime horizon. Costs included drug acquisition and administration for adjuvant and subsequent therapy. Both costs and effectiveness were discounted at 3.0% annually. Cost-effectiveness was evaluated at a hypothetical willingness-to-pay (WTP) threshold of CHF 100,000. Sensitivity was assessed through scenario analyses as well as deterministic and probabilistic sensitivity analyses. Results: Over a lifetime horizon, the total incremental cost for pembrolizumab versus observation was CHF 59,089, providing incremental gains of 0.90 QALYs (1.07 LYs); the incremental cost-effectiveness ratio was CHF 65,299/QALY. Pembrolizumab was deemed cost-effective versus observation, with a 69.9% probability of cost-effectiveness. Limitations: A more recent interim analysis data cut from KEYNOTE-564 with median follow up of 57.2 months has since been published; however, these were not available at the time of analysis. It would likely have minimal impact on transition probabilities from disease-free, and the current approach remains conservative for predicting OS for pembrolizumab. Conclusions: As an adjuvant treatment of RCC post-nephrectomy, pembrolizumab was found to be cost-effective versus observation in Switzerland at a WTP threshold of CHF 100,000/QALY. Policy makers should consider pembrolizumab as an adjuvant treatment for patients with RCC post-nephrectomy when making decisions regarding resource allocation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Temporal association between childhood leukaemia and population growth in Swiss municipalities
- Author
-
Swiss Paediatric Oncology Group, Swiss National Cohort Study Group, Lupatsch, Judith E., Kreis, Christian, Zwahlen, Marcel, Niggli, Felix, Ammann, Roland A., Kuehni, Claudia E., and Spycher, Ben D.
- Published
- 2016
9. The authors' reply: Population mixing and childhood leukaemia
- Author
-
Lupatsch, Judith E., Egger, Matthias, Kuehni, Claudia E., and Spycher, Ben D.
- Published
- 2015
10. Population mixing and the risk of childhood leukaemia in Switzerland: a census-based cohort study
- Author
-
Lupatsch, Judith E., Kuehni, Claudia E., Niggli, Felix, Ammann, Roland A., Egger, Matthias, and Spycher, Ben D.
- Published
- 2015
11. Temporal association between childhood leukaemia and population growth in Swiss municipalities
- Author
-
Lupatsch, Judith E., Kreis, Christian, Zwahlen, Marcel, Niggli, Felix, Ammann, Roland A., Kuehni, Claudia E., Spycher, Ben D., Ammann, R. A., Angst, R., Ansari, M., Beck Popovic, M., Bergstraesser, E., Brazzola, P., Greiner, J., Grotzer, M., Hengartner, H., Kuehne, T., Leibundgut, K., Niggli, F., Rischewski, J., von der Weid, N., Egger, M., Spoerri, A., Zwahlen, M., Puhan, M., Bopp, M., Fäh, D., Künzli, N., Paccaud, F., Oris, M., Schwyn, M., Swiss Paediatric Oncology Group, and Swiss National Cohort Study Group
- Published
- 2016
- Full Text
- View/download PDF
12. Follow-up care of adolescent survivors of childhood cancer: The role of health beliefs
- Author
-
Lupatsch, Judith E., Wengenroth, Laura, Rueegg, Corina S., Teuffel, Oliver, Gumy-Pause, Fabienne, Kuehni, Claudia E., and Michel, Gisela
- Published
- 2016
- Full Text
- View/download PDF
13. Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02/ PREPEC): a pragmatic, multicentre, randomised, superiority trial
- Author
-
Kappos, Elisabeth A, Schulz, Alexandra, Regan, Meredith M, Moffa, Giusi, Harder, Yves, Ribi, Karin, Potter, Shelley, Pusic, Andrea L, Fehr, Mathias K, Hemkens, Lars G, Holzbach, Thomas, Farhadi, Jian, Simonson, Colin, Knauer, Michael, Verstappen, Ralph, Bucher, Heiner C, Zwahlen, Daniel, Zimmermann, Frank, Schwenkglenks, Matthias, Mucklow, Rosine, Shaw, Jane, Bjelic-Radisic, Vesna, Chiorescu, Amelia, Chun, Yoon S, Farah, Subrina, Xiaosong, Chen, Nigard, Linda, Kuemmel, Sherko, Reitsamer, Roland, Hauschild, Maik, Fulco, Ilario, Tausch, Christoph, Fischer, Thomas, Sarlos, Dimitri, Constantinescu, Mihai A, Lupatsch, Judith E, Fitzal, Florian, Heil, Joerg, Matrai, Zoltan, de Boniface, Jana, Kurzeder, Christian, Haug, Martin, and Weber, Walter P
- Subjects
protocols & guidelines ,gynaecological oncology ,Breast Implants ,Mammaplasty ,cancer genetics ,Breast Neoplasms ,610 Medicine & health ,breast tumours ,breast surgery ,plastic & reconstructive surgery ,Nipples ,Humans ,Medicine ,Female ,Surgery ,Breast Implantation ,Mastectomy - Abstract
INTRODUCTION The emphasis on aesthetic outcomes and quality of life (QoL) has motivated surgeons to develop skin-sparing or nipple-sparing mastectomy (SSM/ NSM) for breast cancer treatment or prevention. During the same operation, a so-called immediate breast reconstruction is performed. The breast can be reconstructed by positioning of a breast implant above (prepectoral) or below (subpectoral) the pectoralis major muscle or by using the patients' own tissue (autologous reconstruction). The optimal positioning of the implant prepectoral or subpectoral is currently not clear. Subpectoral implant-based breast reconstruction (IBBR) is still standard care in many countries, but prepectoral IBBR is increasingly performed. This heterogeneity in breast reconstruction practice is calling for randomised clinical trials (RCTs) to guide treatment decisions. METHODS AND ANALYSIS International, pragmatic, multicentre, randomised, superiority trial. The primary objective of this trial is to test whether prepectoral IBBR provides better QoL with respect to long-term (24 months) physical well-being (chest) compared with subpectoral IBBR for patients undergoing SSM or NSM for prevention or treatment of breast cancer. Secondary objectives will compare prepectoral versus subpectoral IBBR in terms of safety, QoL and patient satisfaction, aesthetic outcomes and burden on patients. Total number of patients to be included: 372 (186 per arm). ETHICS AND DISSEMINATION This study will be conducted in compliance with the Declaration of Helsinki. Ethical approval has been obtained for the lead investigator's site by the Ethics Committee 'Ethikkommission Nordwest- und Zentralschweiz' (2020-00256, 26 March 2020). The results of this study will be published in a peer-reviewed medical journal, independent of the results, following the Consolidated Standards of Reporting Trials standards for RCTs and good publication practice. Metadata describing the type, size and content of the datasets will be shared along with the study protocol and case report forms on public repositories adhering to the FAIR (Findability, Accessibility, Interoperability, and Reuse) principles. TRIAL REGISTRATION NUMBER NCT04293146.
- Published
- 2021
- Full Text
- View/download PDF
14. Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02/ PREPEC): a pragmatic, multicentre, randomised, superiority trial
- Author
-
Kappos, Elisabeth A, primary, Schulz, Alexandra, additional, Regan, Meredith M, additional, Moffa, Giusi, additional, Harder, Yves, additional, Ribi, Karin, additional, Potter, Shelley, additional, Pusic, Andrea L, additional, Fehr, Mathias K, additional, Hemkens, Lars G, additional, Holzbach, Thomas, additional, Farhadi, Jian, additional, Simonson, Colin, additional, Knauer, Michael, additional, Verstappen, Ralph, additional, Bucher, Heiner C, additional, Zwahlen, Daniel, additional, Zimmermann, Frank, additional, Schwenkglenks, Matthias, additional, Mucklow, Rosine, additional, Shaw, Jane, additional, Bjelic-Radisic, Vesna, additional, Chiorescu, Amelia, additional, Chun, Yoon S, additional, Farah, Subrina, additional, Xiaosong, Chen, additional, Nigard, Linda, additional, Kuemmel, Sherko, additional, Reitsamer, Roland, additional, Hauschild, Maik, additional, Fulco, Ilario, additional, Tausch, Christoph, additional, Fischer, Thomas, additional, Sarlos, Dimitri, additional, Constantinescu, Mihai A, additional, Lupatsch, Judith E, additional, Fitzal, Florian, additional, Heil, Joerg, additional, Matrai, Zoltan, additional, de Boniface, Jana, additional, Kurzeder, Christian, additional, Haug, Martin, additional, and Weber, Walter P, additional
- Published
- 2021
- Full Text
- View/download PDF
15. Evaluating the cost-effectiveness of early compared to late or no biologic treatment to manage Crohn's disease using real world data
- Author
-
Pillai, Nadia, Lupatsch, Judith E, Dusheiko, Mark, Schwenkglenks, Matthias, Maillard, Michel, Sutherland, C Simone, Pittet, Valérie E H, and University of Zurich
- Subjects
10036 Medical Clinic ,610 Medicine & health ,10060 Epidemiology, Biostatistics and Prevention Institute (EBPI) - Published
- 2020
- Full Text
- View/download PDF
16. Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland – the SAKK 95/16 prostate study
- Author
-
Stoffel, Sandro Tiziano, von Moos, Roger, Thürlimann, Beat, Cathomas, Richard, Gillessen, Silke, Zürrer-Härdi, Ursina, von Briel, Thomas, Anchisi, Sandro, Feller, Anita, Schär, Corinne, Dietrich, Daniel, Schwenkglenks, Matthias; https://orcid.org/0000-0001-7217-1173, Lupatsch, Judith E, Mark, Michael Thomas, Stoffel, Sandro Tiziano, von Moos, Roger, Thürlimann, Beat, Cathomas, Richard, Gillessen, Silke, Zürrer-Härdi, Ursina, von Briel, Thomas, Anchisi, Sandro, Feller, Anita, Schär, Corinne, Dietrich, Daniel, Schwenkglenks, Matthias; https://orcid.org/0000-0001-7217-1173, Lupatsch, Judith E, and Mark, Michael Thomas
- Abstract
BACKGROUND International guidelines state that bone-targeted agents such as denosumab or zoledronic acid at doses used for bone metastasis are not indicated for patients with metastatic castration-sensitive prostate cancer (mCSPC) with bone metastases. Whereas denosumab has never been studied in this patient population, zoledronic acid has been shown to be ineffective in decreasing the risk for skeletal-related events. This study estimates the prevalence and economic consequences of real-world use of bone-targeted agents for mCSPC patients in Switzerland. METHODS To estimate the frequency of bone-targeted agent administration and skeletal-related events, data from a non-interventional, cross-sectional survey involving oncologists across Switzerland (SAKK 95/16) was combined with data from the Swiss National Institute for Cancer Epidemiology and Registration (NICER). Economic parameters were calculated from the perspective of the healthcare system over the median time to prostate-specific antigen (PSA) progression for the extrapolated patient group, using data from NICER. The cost calculation covered costs for bone-targeted agents, their administration and skeletal-related events. The time to PSA progression (33.2 months), as well as the probability and cost of skeletal-related events were derived from the literature. RESULTS The survey was answered by 86 physicians treating 417 patients, of whom 106 (25.4%) had prostate cancer, with 36 (34.0%) of these mCSPC. The majority of mCSPC patients (52.8%, n = 19) received bone-targeted agents monthly. Denosumab was the treatment of choice in 84.2% of patients (n = 16). Extrapolation using data from NICER indicated that 568 mCSPC patients may be treated with bone-targeted agents at doses used for bone metastasis every year in Switzerland, leading to estimated total costs of more than CHF 8.3 million over 33.2 months. Because of its more frequent prescription and higher price, it appears that almost 93% of the total cos
- Published
- 2021
17. Correction: Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.
- Author
-
Mehra, Tarun, Lupatsch, Judith E., Koessler, Thibaud, Dedes, Konstantin, Siebenhüner, Alexander Reinhard, von Moos, Roger, Wicki, Andreas, and Schwenkglenks, Matthias E.
- Subjects
- *
PANCREATIC cancer , *METASTASIS , *OLAPARIB , *ORTHOGRAPHY & spelling - Published
- 2024
- Full Text
- View/download PDF
18. Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland – the SAKK 95/16 prostate study
- Author
-
Stoffel, Sandro T., primary, Von Moos, Roger, additional, Thürlimann, Beat, additional, Cathomas, Richard, additional, Gillessen, Silke, additional, Zürrer-Härdi, Ursina, additional, Von Briel, Thomas, additional, Anchisi, Sandro, additional, Feller, Anita, additional, Schär, Corinne, additional, Dietrich, Daniel, additional, Schwenkglenks, Matthias, additional, Lupatsch, Judith E., additional, and Mark, Michael, additional
- Published
- 2021
- Full Text
- View/download PDF
19. Abstract OT-23-03: Pre- versus sub-pectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02 PREPEC): A pragmatic, multicenter, randomized, superiority trial
- Author
-
Weber, Walter Paul, primary, Kappos, Elisabeth A, additional, Regan, Meredith M, additional, Moffa, Giusi, additional, Harder, Yves, additional, Ribi, Karin, additional, Potter, Shelley, additional, Pusic, Andrea, additional, Fehr, Mathias K, additional, Hemkens, Lars G, additional, Holzbach, Thomas, additional, Farhadi, Jian, additional, Simonson, Colin, additional, Knauer, Michael, additional, Verstappen, Ralph, additional, Bucher, Heiner, additional, Zwahlen, Daniel, additional, Zimmermann, Frank, additional, Schwenkglenks, Matthias, additional, Mucklow, Rosine, additional, Bjelic-Radisic, Vesna, additional, Chiorescu, Amelia, additional, Chun, Yoon, additional, Farah, Subrina, additional, Chen, Xiasong, additional, Nigard, Linda, additional, Kümmel, Sherko, additional, Reitsamer, Roland, additional, Hauschild, Maik, additional, Fulco, Ilario, additional, Tausch, Christoph, additional, Fischer, Thomas, additional, Sarlos, Dimitri, additional, Constantinescu, Mihai, additional, Lupatsch, Judith E, additional, Fitzal, Florian, additional, Heil, Joerg, additional, Mátrai, Zoltán, additional, de Boniface, Jana, additional, Kurzeder, Christian, additional, Haug, Martin, additional, and Schulz, Alexandra, additional
- Published
- 2021
- Full Text
- View/download PDF
20. Evaluating the Cost-Effectiveness of Early Compared with Late or No Biologic Treatment to Manage Crohn's Disease using Real-World Data
- Author
-
Pillai, Nadia, Lupatsch, Judith E, Dusheiko, Mark, Schwenkglenks, Matthias, Maillard, Michel, Sutherland, C Simone, Pittet, Valérie, Swiss IBD Cohort Study group, and Petit, Laëtitia Marie
- Subjects
Crohn’s disease ,Male ,Cost effectiveness ,Cost-Benefit Analysis ,Disease ,Arly biologic initiation ,0302 clinical medicine ,Crohn Disease ,Quality of life ,health care economics and organizations ,Biosimilar Pharmaceuticals / economics ,Crohn's disease ,ddc:618 ,Gastroenterology ,Biosimilar Pharmaceuticals / pharmacology ,Biosimilar ,General Medicine ,Biological Products / economics ,3. Good health ,Crohn Disease / economics ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Female ,Quality-Adjusted Life Years ,Needs Assessment ,Switzerland ,Adult ,medicine.medical_specialty ,Crohn Disease / psychology ,Biologic treatment ,Drug Costs ,Time-to-Treatment ,03 medical and health sciences ,medicine ,Humans ,Time-to-Treatment / statistics & numerical data ,Intensive care medicine ,Biosimilar Pharmaceuticals ,Biological Products ,business.industry ,Time-to-Treatment / economics ,Crohn Disease / therapy ,medicine.disease ,Quality-adjusted life year ,Propensity score matching ,Quality of Life ,Cost-effectiveness ,Biological Products / therapeutic use ,Crohn Disease / diagnosis ,business - Abstract
Background and Aims We evaluated the cost-effectiveness of early [≤2 years after diagnosis] compared with late or no biologic initiation [starting biologics >2 years after diagnosis or no biologic use] for adults with Crohn’s disease in Switzerland. Methods We developed a Markov cohort model over the patient’s lifetime, from the health system and societal perspectives. Transition probabilities, quality of life, and costs were estimated using real-world data. Propensity score matching was used to ensure comparability between patients in the early [intervention] and late/no [comparator] biologic initiation strategies. The incremental cost-effectiveness ratio [ICER] per quality-adjusted life year [QALY] gained is reported in Swiss francs [CHF]. Sensitivity and scenario analyses were performed. Results Total costs and QALYs were higher for the intervention [CHF384 607; 16.84 QALYs] compared with the comparator [CHF340 800; 16.75 QALYs] strategy, resulting in high ICERs [health system: CHF887 450 per QALY; societal: CHF449 130 per QALY]. In probabilistic sensitivity analysis, assuming a threshold of CHF100 000 per QALY, the probability that the intervention strategy was cost-effective was 0.1 and 0.25 from the health system and societal perspectives, respectively. In addition, ICERs improved when we assumed a 30% reduction in biologic prices [health system: CHF134 502 per QALY; societal: intervention dominant]. Conclusions Early biologic use was not cost-effective, considering a threshold of CHF100 000 per QALY compared with late/no biologic use. However, early identification of patients likely to need biologics and future drug price reductions through increased availability of biosimilars may improve the cost-effectiveness of an early treatment approach.
- Published
- 2020
21. Background ionizing radiation and the risk of childhood cancer: a census-based nationwide cohort study
- Author
-
Spycher, Ben D., Lupatsch, Judith E., Zwahlen, Marcel, Roosli, Martin, Niggli, Felix, Grotzer, Michael A., Rischewski, Johannes, Egger, Matthias, and Kuehni, Claudia E.
- Subjects
Risk factors ,Demographic aspects ,Health aspects ,Childhood cancer -- Risk factors -- Demographic aspects ,Ionizing radiation -- Health aspects ,Cancer in children -- Risk factors -- Demographic aspects - Abstract
Introduction Ionizing radiation is a known risk factor for cancer [United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) 2006]. For a given radiation dose, children are at [...], BACKGROUND: Exposure to medium or high doses of ionizing radiation is a known risk factor for cancer in children. The extent to which low-dose radiation from natural sources contributes to the risk of childhood cancer remains unclear. OBJECTIVES: In a nationwide census-based cohort study, we investigated whether the incidence of childhood cancer was associated with background radiation from terrestrial gamma and cosmic rays. METHODS: Children < 16 years of age in the Swiss National Censuses in 1990 and 2000 were included. The follow-up period lasted until 2008, and incident cancer cases were identified from the Swiss Childhood Cancer Registry. A radiation model was used to predict dose rates from terrestrial and cosmic radiation at locations of residence. Cox regression models were used to assess associations between cancer risk and dose rates and cumulative dose since birth. RESULTS: Among 2,093,660 children included at census, 1,782 incident cases of cancer were identified including 530 with leukemia, 328 with lymphoma, and 423 with a tumor of the central nervous system (CNS). Hazard ratios for each millisievert increase in cumulative dose of external radiation were 1.03 (95% CI: 1.01, 1.05) for any cancer, 1.04 (95% CI: 1.00, 1.08) for leukemia, 1.01 (95% CI: 0.96, 1.05) for lymphoma, and 1.04 (95% CI: 1.00, 1.08) for CNS tumors. Adjustment for a range of potential confounders had little effect on the results. CONCLUSIONS: Our study suggests that background radiation may contribute to the risk of cancer in children, including leukemia and CNS tumors. http://dx.doi.org/ 10.1289/ehp.1408548
- Published
- 2015
- Full Text
- View/download PDF
22. Childhood brain tumours, early infections and immune stimulation: A pooled analysis of the ESCALE and ESTELLE case-control studies (SFCE, France)
- Author
-
Lupatsch, Judith E, Bailey, Helen D, Lacour, Brigitte, Dufour, Christelle, Bertozzi, Anne-Isabelle, Leblond, Pierre, Faure-Conter, Cécile, Pellier, Isabelle, Freycon, Claire, Doz, François, Puget, Stéphanie, Ducassou, Stéphane, Orsi, Laurent, and Clavel, Jacqueline
- Subjects
610 Medicine & health ,360 Social problems & social services - Abstract
BACKGROUND Few studies have investigated whether early infections and factors potentially related to early immune stimulation might be involved in the aetiology of childhood brain tumours (CBT). In this study, we investigated the associations between CBT with early day-care attendance, history of early common infections, atopic conditions (asthma/wheezing, eczema, allergic rhinitis), early farm residence/visits and contact with animals. METHODS We pooled data from two nationwide French case-control studies, the ESCALE and ESTELLE studies. Children with a CBT diagnosed between 1 and 14 years of age were identified directly from the French National Registry of Childhood Cancers, while population controls were recruited from telephone subscribers. Odds-ratios (OR) and 95% confidence intervals (CI) were estimated using logistic regression adjusted for potential confounders. RESULTS The analyses included 469 cases and 2719 controls. We found no association between attending a day-care centre (OR: 0.9, 95%CI: 0.7-1.2) or having had repeated common infections (OR: 0.9, 95%CI: 0.7-1.2) in the first year of life and the risk of CBT. There was also no association with a history of asthma/wheezing (OR: 0.8, 95%CI: 0.56-1.1). Farm visits (OR: 0.6, 95%CI: 0.5-0.8) as well as contact with pets (OR: 0.8, 95%CI: 0.6-1.0) in the first year of life were inversely associated with CBT. CONCLUSIONS Our findings suggest a protective effect of early farm visits and contact with pets, but not with other markers of early immune stimulation. This might be related to immune stimulation but needs further investigation.
- Published
- 2018
- Full Text
- View/download PDF
23. Space–time clustering of childhood cancers: a systematic review and pooled analysis
- Author
-
Kreis, Christian, primary, Doessegger, Eliane, additional, Lupatsch, Judith E., additional, and Spycher, Ben D., additional
- Published
- 2018
- Full Text
- View/download PDF
24. Neighbourhood child population density as a proxy measure for exposure to respiratory infections in the first year of life: A validation study
- Author
-
Lupatsch, Judith E., primary, Kreis, Christian, additional, Korten, Insa, additional, Latzin, Philipp, additional, Frey, Urs, additional, Kuehni, Claudia E., additional, and Spycher, Ben D., additional
- Published
- 2018
- Full Text
- View/download PDF
25. Space-Time Clustering of Childhood Leukemia: Evidence of an Association with ETV6-RUNX1 (TEL-AML1) Fusion
- Author
-
Swiss Paediatric Oncology Group, Swiss National Cohor Study Group, Kuehni, Claudia E, Kreis, Christian, Spycher, Ben D, Lupatsch, Judith E, Egger, Matthias, and Niggli, Felix
- Subjects
360 Social problems & social services ,lcsh:R ,lcsh:Medicine ,lcsh:Q ,610 Medicine & health ,lcsh:Science - Abstract
BACKGROUND Many studies have observed space-time clustering of childhood leukemia (CL) yet few have attempted to elicit etiological clues from such clustering. We recently reported space-time clustering of CL around birth, and now aim to generate etiological hypotheses by comparing clustered and nonclustered cases. We also investigated whether the clustering resulted from many small aggregations of cases or from a few larger clusters. METHODS We identified cases of persons born and diagnosed between 1985 and 2014 at age 0-15 years from the Swiss Childhood Cancer Registry. We determined spatial and temporal lags that maximized evidence of clustering based on the Knox test and classified cases born within these lags from another case as clustered. Using logistic regression adjusted for child population density, we determined whether clustering status was associated with age at diagnosis, immunophenotype, cytogenetic subtype, perinatal and socioeconomic characteristics, and pollution sources. RESULTS Analyses included 1,282 cases of which 242 were clustered (born within 1 km and 2 years from another case). Of all investigated characteristics only the t(12;21)(p13;q22) translocation (resulting in ETV6-RUNX1 fusion) differed significantly in prevalence between clustered and nonclustered cases (40% and 25%, respectively; adjusted OR 2.54 [1.52-4.23]; p = 0.003). Spatio-temporal clustering was driven by an excess of aggregations of two or three children rather than by a few large clusters. CONCLUSION Our findings suggest ETV6-RUNX1 is associated with space-time clustering of CL and are consistent with an infection interacting with that oncogene in early life leading to clinical leukemia.
- Published
- 2017
- Full Text
- View/download PDF
26. Physicians' experiences with follow-up care of childhood cancer survivors – challenges and needs
- Author
-
Michel, Gisela (Autor/in), Gianinazzi, Micol E., Vetsch, Janine (Author), Mader, Luzius Adrian (Author), Lupatsch, Judith E., von der Weid, Nicolas, and Rueegg, Corina S.
- Abstract
BACKGROUND: Regular follow-up care is essential for childhood cancer survivors, but we know little about physicians' experience with it. We aimed to describe: (1) involvement of Swiss physicians in follow-up care; (2) content of follow-up care provided; (3) problems encountered; and (4) additional resources needed. MATERIALS AND METHODS: Within this cross-sectional survey we sent adapted questionnaires via professional associations to a sample of medical oncologists (MOs), paediatric oncologists (POs), general practitioners (GPs) and paediatricians (P) in Switzerland. Only oncologists involved in follow-up care were asked to report problems. GPs and Ps not involved in follow-up could indicate why. All physicians were asked about the content of follow-up care provided and additional resources needed. RESULTS: A total of 183 physicians responded (27 MO, 13 PO, 122 GP, 21 P). Involved in follow-up were 81% of MOs, 85% of POs, 39% of GPs and 81% of Ps. Follow-up content differed between oncologists (MO and PO) and generalists (GP and P), with generalists examining or informing less in regard to the former cancer. POs reported more problems than MOs: many POs reported problems with transition of survivors to adult care (91%), and because of financial resources (73%) and time restraints (73%). MOs reported most problems during transition (23%). Not being aware of a survivor was the most common reason for GPs and Ps not participating in follow-up (74%). All groups reported a need for standardised protocols (85–91%) and specialised training (55–73%). GPs (94%) and Ps (100%) additionally desired more support from oncologists. CONCLUSIONS: To improve quality and efficiency of follow-up care a national follow-up care model including standardised protocols and guidelines needs to be developed.
- Published
- 2017
- Full Text
- View/download PDF
27. Space-Time Clustering of Childhood Leukemia: Evidence of an Association with ETV6-RUNX1 (TEL-AML1) Fusion
- Author
-
Kreis, Christian, Lupatsch, Judith E, Niggli, Felix, Egger, Matthias, Kuehni, Claudia E, Spycher, Ben D, Swiss Paediatric Oncology Group, Swiss National Cohort Study Group, and University of Zurich
- Subjects
1000 Multidisciplinary ,10036 Medical Clinic ,1300 General Biochemistry, Genetics and Molecular Biology ,610 Medicine & health ,1100 General Agricultural and Biological Sciences - Published
- 2017
- Full Text
- View/download PDF
28. Temporal association between childhood leukaemia and population growth in Swiss municipalities
- Author
-
Lupatsch, Judith E, Kreis, Christian, Zwahlen, Marcel, Niggli, Felix, Ammann, Roland A, Kuehni, Claudia E, Spycher, Ben D, Swiss Paediatric Oncology Group, Swiss National Cohort Study Group, University of Zurich, and Spycher, Ben D
- Subjects
10036 Medical Clinic ,610 Medicine & health ,2713 Epidemiology - Published
- 2016
29. Follow-Up Care of Adolescent Cancer Survivors: The Role of Health-Beliefs
- Author
-
Lupatsch, Judith E., Wengenroth, Laura, Rueegg, Corina S., Teuffel, Oliver, Gumy-Pause, Fabienne, Kuehni, Claudia E., and Michel, Gisela
- Subjects
humanities - Abstract
Background Little is known about follow‐up care attendance of adolescent survivors of childhood cancer, and which factors foster or hinder attendance. Attending follow‐up care is especially important for adolescent survivors to allow for a successful transition into adult care. We aimed to (i) describe the proportion of adolescent survivors attending follow‐up care; (ii) describe adolescents' health beliefs; and (iii) identify the association of health beliefs, demographic, and medical factors with follow‐up care attendance. Procedure Of 696 contacted adolescent survivors diagnosed with cancer at ≤16 years of age, ≥5 years after diagnosis, and aged 16–21 years at study, 465 (66.8%) completed the Swiss Childhood Cancer Survivor Study questionnaire. We assessed follow‐up care attendance and health beliefs, and extracted demographic and medical information from the Swiss Childhood Cancer Registry. Cross‐sectional data were analyzed using descriptive statistics and logistic regression models. Results Overall, 56% of survivors reported attending follow‐up care. Most survivors (80%) rated their susceptibility for late effects as low and believed that follow‐up care may detect and prevent late effects (92%). Few (13%) believed that follow‐up care is not necessary. Two health beliefs were associated with follow‐up care attendance (perceived benefits: odds ratio [OR]: 1.56; 95% confidence interval [CI]: 1.07–2.27; perceived barriers: OR: 0.70; 95%CI: 0.50–1.00). Conclusions We show that health beliefs are associated with actual follow‐up care attendance of adolescent survivors of childhood cancer. A successful model of health promotion in adolescent survivors should, therefore, highlight the benefits and address the barriers to keep adolescent survivors in follow‐up care. Pediatr Blood Cancer © 2015 Wiley Periodicals, Inc.
- Published
- 2016
- Full Text
- View/download PDF
30. Space-Time Clustering of Childhood Leukemia: Evidence of an Association with ETV6-RUNX1 (TEL-AML1) Fusion
- Author
-
Kreis, Christian; https://orcid.org/0000-0001-5273-1954, Lupatsch, Judith E, Niggli, Felix, Egger, Matthias, Kuehni, Claudia E, Spycher, Ben D, Swiss Paediatric Oncology Group, Swiss National Cohort Study Group, Kreis, Christian; https://orcid.org/0000-0001-5273-1954, Lupatsch, Judith E, Niggli, Felix, Egger, Matthias, Kuehni, Claudia E, Spycher, Ben D, Swiss Paediatric Oncology Group, and Swiss National Cohort Study Group
- Abstract
BACKGROUND: Many studies have observed space-time clustering of childhood leukemia (CL) yet few have attempted to elicit etiological clues from such clustering. We recently reported space-time clustering of CL around birth, and now aim to generate etiological hypotheses by comparing clustered and nonclustered cases. We also investigated whether the clustering resulted from many small aggregations of cases or from a few larger clusters. METHODS: We identified cases of persons born and diagnosed between 1985 and 2014 at age 0-15 years from the Swiss Childhood Cancer Registry. We determined spatial and temporal lags that maximized evidence of clustering based on the Knox test and classified cases born within these lags from another case as clustered. Using logistic regression adjusted for child population density, we determined whether clustering status was associated with age at diagnosis, immunophenotype, cytogenetic subtype, perinatal and socioeconomic characteristics, and pollution sources. RESULTS: Analyses included 1,282 cases of which 242 were clustered (born within 1 km and 2 years from another case). Of all investigated characteristics only the t(12;21)(p13;q22) translocation (resulting in ETV6-RUNX1 fusion) differed significantly in prevalence between clustered and nonclustered cases (40% and 25%, respectively; adjusted OR 2.54 [1.52-4.23]; p = 0.003). Spatio-temporal clustering was driven by an excess of aggregations of two or three children rather than by a few large clusters. CONCLUSION: Our findings suggest ETV6-RUNX1 is associated with space-time clustering of CL and are consistent with an infection interacting with that oncogene in early life leading to clinical leukemia.
- Published
- 2017
31. Background ionizing radiation and the risk of childhood cancer: a census-based nationwide cohort study
- Author
-
Spycher, Ben D, Lupatsch, Judith E, Zwahlen, Marcel, Röösli, Martin, Niggli, Felix, Grotzer, Michael A, Rischewski, Johannes, Egger, Matthias, Kuehni, Claudia E, Spycher, Ben D, Lupatsch, Judith E, Zwahlen, Marcel, Röösli, Martin, Niggli, Felix, Grotzer, Michael A, Rischewski, Johannes, Egger, Matthias, and Kuehni, Claudia E
- Abstract
BACKGROUND Exposure to medium or high doses of ionizing radiation is a known risk factor for cancer in children. The extent to which low-dose radiation from natural sources contributes to the risk of childhood cancer remains unclear. OBJECTIVES In a nationwide census-based cohort study, we investigated whether the incidence of childhood cancer was associated with background radiation from terrestrial gamma and cosmic rays. METHODS Children < 16 years of age in the Swiss National Censuses in 1990 and 2000 were included. The follow-up period lasted until 2008, and incident cancer cases were identified from the Swiss Childhood Cancer Registry. A radiation model was used to predict dose rates from terrestrial and cosmic radiation at locations of residence. Cox regression models were used to assess associations between cancer risk and dose rates and cumulative dose since birth. RESULTS Among 2,093,660 children included at census, 1,782 incident cases of cancer were identified including 530 with leukemia, 328 with lymphoma, and 423 with a tumor of the central nervous system (CNS). Hazard ratios for each millisievert increase in cumulative dose of external radiation were 1.03 (95% CI: 1.01, 1.05) for any cancer, 1.04 (95% CI: 1.00, 1.08) for leukemia, 1.01 (95% CI: 0.96, 1.05) for lymphoma, and 1.04 (95% CI: 1.00, 1.08) for CNS tumors. Adjustment for a range of potential confounders had little effect on the results. CONCLUSIONS Our study suggests that background radiation may contribute to the risk of cancer in children, including leukemia and CNS tumors.
- Published
- 2015
32. Population Mixing and the Risk of Childhood Leukemia: a Nationwide Cohort Study
- Author
-
Lupatsch*, Judith E, primary, Kuehni, Claudia E, additional, Niggli, Felix, additional, Ammann, Roland A, additional, Egger, Matthias, additional, and Spycher, Ben D, additional
- Published
- 2014
- Full Text
- View/download PDF
33. Physicians' experience with follow-up care of childhood cancer survivors - challenges and needs
- Author
-
Michel, Gisela, Gianinazzi, Micol Eva, Vetsch, Janine, Mader, Luzius, Lupatsch, Judith E, Von Der Weid, Nicolas X, and Rueegg, Corina Silvia
- Subjects
610 Medicine & health ,360 Social problems & social services ,3. Good health - Abstract
BACKGROUND Regular follow-up care is essential for childhood cancer survivors, but we know little about physicians' experience with it. We aimed to describe: (1) involvement of Swiss physicians in follow-up care; (2) content of follow-up care provided; (3) problems encountered; and (4) additional resources needed. MATERIALS AND METHODS Within this cross-sectional survey we sent adapted questionnaires via professional associations to a sample of medical oncologists (MOs), paediatric oncologists (POs), general practitioners (GPs) and paediatricians (P) in Switzerland. Only oncologists involved in follow-up care were asked to report problems. GPs and Ps not involved in follow-up could indicate why. All physicians were asked about the content of follow-up care provided and additional resources needed. RESULTS A total of 183 physicians responded (27 MO, 13 PO, 122 GP, 21 P). Involved in follow-up were 81% of MOs, 85% of POs, 39% of GPs and 81% of Ps. Follow-up content differed between oncologists (MO and PO) and generalists (GP and P), with generalists examining or informing less in regard to the former cancer. POs reported more problems than MOs: many POs reported problems with transition of survivors to adult care (91%), and because of financial resources (73%) and time restraints (73%). MOs reported most problems during transition (23%). Not being aware of a survivor was the most common reason for GPs and Ps not participating in follow-up (74%). All groups reported a need for standardised protocols (85-91%) and specialised training (55-73%). GPs (94%) and Ps (100%) additionally desired more support from oncologists. CONCLUSIONS To improve quality and efficiency of follow-up care a national follow-up care model including standardised protocols and guidelines needs to be developed.
34. Background ionizing radiation and the risk of childhood cancer : a census-based nationwide cohort study
- Author
-
Spycher, Ben D., Lupatsch, Judith E., Zwahlen, Marcel, Röösli, Martin, Niggli, Felix, Grotzer, Michael A., Rischewski, Johannes, Egger, Matthias, and Kuehni, Claudia E.
- Subjects
3. Good health
35. Population mixing and the risk of childhood leukaemia in Switzerland: a census-based cohort study
- Author
-
Lupatsch, Judith E, Kuehni, Claudia E, Niggli, Felix, Ammann, Roland A, Egger, Matthias, and Spycher, Ben D
- Subjects
610 Medicine & health ,360 Social problems & social services ,3. Good health - Abstract
Childhood leukaemia (CL) may have an infectious cause and population mixing may therefore increase the risk of CL. We aimed to determine whether CL was associated with population mixing in Switzerland. We followed children aged
36. Neighbourhood child population density as a proxy measure for exposure to respiratory infections in the first year of life: A validation study
- Author
-
Lupatsch, Judith E, Kreis, Christian, Korten, Insa Christina Severine, Latzin, Philipp, Frey, Urs, Kuehni, Claudia E, and Spycher, Ben D
- Subjects
610 Medicine & health ,360 Social problems & social services ,3. Good health - Abstract
BACKGROUND Assessing exposure to infections in early childhood is of interest in many epidemiological investigations. Because exposure to infections is difficult to measure directly, epidemiological studies have used surrogate measures available from routine data such as birth order and population density. However, the association between population density and exposure to infections is unclear. We assessed whether neighbourhood child population density is associated with respiratory infections in infants. METHODS With the Basel-Bern lung infant development study (BILD), a prospective Swiss cohort study of healthy neonates, respiratory symptoms and infections were assessed by weekly telephone interviews with the mother throughout the first year of life. Using population census data, we calculated neighbourhood child density as the number of children < 16 years of age living within a 250 m radius around the residence of each child. We used negative binomial regression models to assess associations between neighbourhood child density and the number of weeks with respiratory infections and adjusted for potential confounders including the number of older siblings, day-care attendance and duration of breastfeeding. We investigated possible interactions between neighbourhood child population density and older siblings assuming that older siblings mix with other children in the neighbourhood. RESULTS The analyses included 487 infants. We found no evidence of an association between quintiles of neighbourhood child density and number of respiratory symptoms (p = 0.59, incidence rate ratios comparing highest to lowest quintile: 1.15, 95%-confidence interval: 0.90-1.47). There was no evidence of interaction with older siblings (p = 0.44). Results were similar in crude and in fully adjusted models. CONCLUSIONS Our study suggests that in Switzerland neighbourhood child density is a poor proxy for exposure to infections in infancy.
37. Follow-Up Care of Adolescent Cancer Survivors: The Role of Health-Beliefs
- Author
-
Lupatsch, Judith E., Wengenroth, Laura, Rueegg, Corina S., Teuffel, Oliver, Gumy-Pause, Fabienne, Kuehni, Claudia E., and Michel, Gisela
- Subjects
humanities ,3. Good health - Abstract
Background Little is known about follow‐up care attendance of adolescent survivors of childhood cancer, and which factors foster or hinder attendance. Attending follow‐up care is especially important for adolescent survivors to allow for a successful transition into adult care. We aimed to (i) describe the proportion of adolescent survivors attending follow‐up care; (ii) describe adolescents' health beliefs; and (iii) identify the association of health beliefs, demographic, and medical factors with follow‐up care attendance. Procedure Of 696 contacted adolescent survivors diagnosed with cancer at ≤16 years of age, ≥5 years after diagnosis, and aged 16–21 years at study, 465 (66.8%) completed the Swiss Childhood Cancer Survivor Study questionnaire. We assessed follow‐up care attendance and health beliefs, and extracted demographic and medical information from the Swiss Childhood Cancer Registry. Cross‐sectional data were analyzed using descriptive statistics and logistic regression models. Results Overall, 56% of survivors reported attending follow‐up care. Most survivors (80%) rated their susceptibility for late effects as low and believed that follow‐up care may detect and prevent late effects (92%). Few (13%) believed that follow‐up care is not necessary. Two health beliefs were associated with follow‐up care attendance (perceived benefits: odds ratio [OR]: 1.56; 95% confidence interval [CI]: 1.07–2.27; perceived barriers: OR: 0.70; 95%CI: 0.50–1.00). Conclusions We show that health beliefs are associated with actual follow‐up care attendance of adolescent survivors of childhood cancer. A successful model of health promotion in adolescent survivors should, therefore, highlight the benefits and address the barriers to keep adolescent survivors in follow‐up care. Pediatr Blood Cancer © 2015 Wiley Periodicals, Inc., + ID der Publikation: unilu_6276 + Sprache: Englisch + Letzte Aktualisierung: 2019-08-27 12:04:44
38. Physicians' experiences with follow-up care of childhood cancer survivors – challenges and needs
- Author
-
Michel, Gisela (Autor/in), Gianinazzi, Micol E., Vetsch, Janine (Author), Mader, Luzius Adrian (Author), Lupatsch, Judith E., von der Weid, Nicolas, and Rueegg, Corina S.
- Subjects
3. Good health - Abstract
BACKGROUND: Regular follow-up care is essential for childhood cancer survivors, but we know little about physicians' experience with it. We aimed to describe: (1) involvement of Swiss physicians in follow-up care; (2) content of follow-up care provided; (3) problems encountered; and (4) additional resources needed. MATERIALS AND METHODS: Within this cross-sectional survey we sent adapted questionnaires via professional associations to a sample of medical oncologists (MOs), paediatric oncologists (POs), general practitioners (GPs) and paediatricians (P) in Switzerland. Only oncologists involved in follow-up care were asked to report problems. GPs and Ps not involved in follow-up could indicate why. All physicians were asked about the content of follow-up care provided and additional resources needed. RESULTS: A total of 183 physicians responded (27 MO, 13 PO, 122 GP, 21 P). Involved in follow-up were 81% of MOs, 85% of POs, 39% of GPs and 81% of Ps. Follow-up content differed between oncologists (MO and PO) and generalists (GP and P), with generalists examining or informing less in regard to the former cancer. POs reported more problems than MOs: many POs reported problems with transition of survivors to adult care (91%), and because of financial resources (73%) and time restraints (73%). MOs reported most problems during transition (23%). Not being aware of a survivor was the most common reason for GPs and Ps not participating in follow-up (74%). All groups reported a need for standardised protocols (85–91%) and specialised training (55–73%). GPs (94%) and Ps (100%) additionally desired more support from oncologists. CONCLUSIONS: To improve quality and efficiency of follow-up care a national follow-up care model including standardised protocols and guidelines needs to be developed., + ID der Publikation: unilu_23965 + Sprache: Englisch + Letzte Aktualisierung: 2018-12-28 09:59:44
39. Background Ionizing Radiation and the Risk of Childhood Cancer: A Census-Based Nationwide Cohort Study
- Author
-
Spycher, Ben D, Lupatsch, Judith E, Zwahlen, Marcel, Röösli, Martin, Niggli, Felix, Grotzer, Michael A, Rischewski, Johannes, Egger, Matthias, and Kuehni, Claudia E
- Subjects
610 Medicine & health ,360 Social problems & social services ,3. Good health - Abstract
BACKGROUND Exposure to medium or high doses of ionizing radiation is a known risk factor for cancer in children. The extent to which low dose radiation from natural sources contributes to the risk of childhood cancer remains unclear. OBJECTIVES In a nationwide census-based cohort study, we investigated whether the incidence of childhood cancer was associated with background radiation from terrestrial gamma and cosmic rays. METHODS Children aged
40. Physicians' experiences with follow-up care of childhood cancer survivors – challenges and needs
- Author
-
Michel, Gisela (Autor/in), Gianinazzi, Micol E., Vetsch, Janine (Author), Mader, Luzius Adrian (Author), Lupatsch, Judith E., von der Weid, Nicolas, and Rueegg, Corina S.
- Subjects
3. Good health - Abstract
BACKGROUND: Regular follow-up care is essential for childhood cancer survivors, but we know little about physicians' experience with it. We aimed to describe: (1) involvement of Swiss physicians in follow-up care; (2) content of follow-up care provided; (3) problems encountered; and (4) additional resources needed. MATERIALS AND METHODS: Within this cross-sectional survey we sent adapted questionnaires via professional associations to a sample of medical oncologists (MOs), paediatric oncologists (POs), general practitioners (GPs) and paediatricians (P) in Switzerland. Only oncologists involved in follow-up care were asked to report problems. GPs and Ps not involved in follow-up could indicate why. All physicians were asked about the content of follow-up care provided and additional resources needed. RESULTS: A total of 183 physicians responded (27 MO, 13 PO, 122 GP, 21 P). Involved in follow-up were 81% of MOs, 85% of POs, 39% of GPs and 81% of Ps. Follow-up content differed between oncologists (MO and PO) and generalists (GP and P), with generalists examining or informing less in regard to the former cancer. POs reported more problems than MOs: many POs reported problems with transition of survivors to adult care (91%), and because of financial resources (73%) and time restraints (73%). MOs reported most problems during transition (23%). Not being aware of a survivor was the most common reason for GPs and Ps not participating in follow-up (74%). All groups reported a need for standardised protocols (85–91%) and specialised training (55–73%). GPs (94%) and Ps (100%) additionally desired more support from oncologists. CONCLUSIONS: To improve quality and efficiency of follow-up care a national follow-up care model including standardised protocols and guidelines needs to be developed.
41. Birth characteristics and childhood leukemia in Switzerland: a register-based case-control study
- Author
-
Lupatsch, Judith E., Kreis, Christian, Konstantinoudis, Garyfallos, Ansari, Marc, Kuehni, Claudia E., and Spycher, Ben D.
- Subjects
hemic and lymphatic diseases ,610 Medicine & health ,360 Social problems & social services ,3. Good health - Abstract
PURPOSE Initial genetic alterations in the development of childhood leukemia occur in utero or before conception; both genetic and environmental factors are suspected to play a role. We aimed to investigate the associations between childhood leukemia and perinatal characteristics including birth order, birth interval to older siblings, parental age, birth weight, and multiple birth. METHODS We identified cases diagnosed between 1981 and 2015 and born in Switzerland between 1969 and 2015 from the Swiss Childhood Cancer Registry and randomly sampled five controls per case from national birth records matched on date of birth, sex, and municipality of residence at birth. We used conditional logistic regression to investigate associations between perinatal characteristics and leukemia at ages 0-15 and 0-4 years, and the subtypes acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). RESULTS The study included 1,403 cases of leukemia. We observed increased risks associated with high birth weight (adjusted OR 1.37, 95% CI 1.12-1.69) and multiple birth (1.89, 1.24-2.86). These associations were similar for ALL and stronger for leukemia at ages 0-4 years. For AML, we observed an increased risk for higher birth order (3.08, 0.43-22.03 for fourth or later born children). We found no associations with other perinatal characteristics. CONCLUSION This register-based case-control study adds to the existing evidence of a positive association between high birth weight and risk of childhood leukemia. Furthermore, it suggests children from multiple births are at an increased risk of leukemia.
42. Follow-up care of adolescent survivors of childhood cancer: The role of health beliefs
- Author
-
Lupatsch, Judith E., Wengenroth, Laura, Rueegg, Corina S., Teuffel, Oliver, Gumy-Pause, Fabienne, Kuehni, Claudia E., and Michel, Gisela
- Subjects
610 Medicine & health ,humanities ,360 Social problems & social services ,3. Good health - Abstract
BACKGROUND Little is known about follow-up care attendance of adolescent survivors of childhood cancer, and which factors foster or hinder attendance. Attending follow-up care is especially important for adolescent survivors to allow for a successful transition into adult care. We aimed to (i) describe the proportion of adolescent survivors attending follow-up care; (ii) describe adolescents' health beliefs; and (iii) identify the association of health beliefs, demographic, and medical factors with follow-up care attendance. PROCEDURE Of 696 contacted adolescent survivors diagnosed with cancer at ≤16 years of age, ≥5 years after diagnosis, and aged 16-21 years at study, 465 (66.8%) completed the Swiss Childhood Cancer Survivor Study questionnaire. We assessed follow-up care attendance and health beliefs, and extracted demographic and medical information from the Swiss Childhood Cancer Registry. Cross-sectional data were analyzed using descriptive statistics and logistic regression models. RESULTS Overall, 56% of survivors reported attending follow-up care. Most survivors (80%) rated their susceptibility for late effects as low and believed that follow-up care may detect and prevent late effects (92%). Few (13%) believed that follow-up care is not necessary. Two health beliefs were associated with follow-up care attendance (perceived benefits: odds ratio [OR]: 1.56; 95% confidence interval [CI]: 1.07-2.27; perceived barriers: OR: 0.70; 95%CI: 0.50-1.00). CONCLUSIONS We show that health beliefs are associated with actual follow-up care attendance of adolescent survivors of childhood cancer. A successful model of health promotion in adolescent survivors should, therefore, highlight the benefits and address the barriers to keep adolescent survivors in follow-up care. Pediatr Blood Cancer © 2015 Wiley Periodicals, Inc.
43. Follow-Up Care of Adolescent Cancer Survivors: The Role of Health-Beliefs
- Author
-
Lupatsch, Judith E., Wengenroth, Laura, Rueegg, Corina S., Teuffel, Oliver, Gumy-Pause, Fabienne, Kuehni, Claudia E., and Michel, Gisela
- Subjects
humanities ,3. Good health - Abstract
Background Little is known about follow‐up care attendance of adolescent survivors of childhood cancer, and which factors foster or hinder attendance. Attending follow‐up care is especially important for adolescent survivors to allow for a successful transition into adult care. We aimed to (i) describe the proportion of adolescent survivors attending follow‐up care; (ii) describe adolescents' health beliefs; and (iii) identify the association of health beliefs, demographic, and medical factors with follow‐up care attendance. Procedure Of 696 contacted adolescent survivors diagnosed with cancer at ≤16 years of age, ≥5 years after diagnosis, and aged 16–21 years at study, 465 (66.8%) completed the Swiss Childhood Cancer Survivor Study questionnaire. We assessed follow‐up care attendance and health beliefs, and extracted demographic and medical information from the Swiss Childhood Cancer Registry. Cross‐sectional data were analyzed using descriptive statistics and logistic regression models. Results Overall, 56% of survivors reported attending follow‐up care. Most survivors (80%) rated their susceptibility for late effects as low and believed that follow‐up care may detect and prevent late effects (92%). Few (13%) believed that follow‐up care is not necessary. Two health beliefs were associated with follow‐up care attendance (perceived benefits: odds ratio [OR]: 1.56; 95% confidence interval [CI]: 1.07–2.27; perceived barriers: OR: 0.70; 95%CI: 0.50–1.00). Conclusions We show that health beliefs are associated with actual follow‐up care attendance of adolescent survivors of childhood cancer. A successful model of health promotion in adolescent survivors should, therefore, highlight the benefits and address the barriers to keep adolescent survivors in follow‐up care. Pediatr Blood Cancer © 2015 Wiley Periodicals, Inc.
44. Evaluating the Cost-Effectiveness of Early Compared with Late or No Biologic Treatment to Manage Crohn's Disease using Real-World Data.
- Author
-
Pillai N, Lupatsch JE, Dusheiko M, Schwenkglenks M, Maillard M, Sutherland CS, and Pittet VEH
- Subjects
- Adult, Biosimilar Pharmaceuticals economics, Biosimilar Pharmaceuticals pharmacology, Cost-Benefit Analysis, Drug Costs, Female, Humans, Male, Needs Assessment, Quality-Adjusted Life Years, Switzerland, Biological Products economics, Biological Products therapeutic use, Crohn Disease diagnosis, Crohn Disease economics, Crohn Disease psychology, Crohn Disease therapy, Quality of Life, Time-to-Treatment economics, Time-to-Treatment statistics & numerical data
- Abstract
Background and Aims: We evaluated the cost-effectiveness of early [≤2 years after diagnosis] compared with late or no biologic initiation [starting biologics >2 years after diagnosis or no biologic use] for adults with Crohn's disease in Switzerland., Methods: We developed a Markov cohort model over the patient's lifetime, from the health system and societal perspectives. Transition probabilities, quality of life, and costs were estimated using real-world data. Propensity score matching was used to ensure comparability between patients in the early [intervention] and late/no [comparator] biologic initiation strategies. The incremental cost-effectiveness ratio [ICER] per quality-adjusted life year [QALY] gained is reported in Swiss francs [CHF]. Sensitivity and scenario analyses were performed., Results: Total costs and QALYs were higher for the intervention [CHF384 607; 16.84 QALYs] compared with the comparator [CHF340 800; 16.75 QALYs] strategy, resulting in high ICERs [health system: CHF887 450 per QALY; societal: CHF449 130 per QALY]. In probabilistic sensitivity analysis, assuming a threshold of CHF100 000 per QALY, the probability that the intervention strategy was cost-effective was 0.1 and 0.25 from the health system and societal perspectives, respectively. In addition, ICERs improved when we assumed a 30% reduction in biologic prices [health system: CHF134 502 per QALY; societal: intervention dominant]., Conclusions: Early biologic use was not cost-effective, considering a threshold of CHF100 000 per QALY compared with late/no biologic use. However, early identification of patients likely to need biologics and future drug price reductions through increased availability of biosimilars may improve the cost-effectiveness of an early treatment approach., (Copyright © 2019 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
45. Physicians' experience with follow-up care of childhood cancer survivors - challenges and needs.
- Author
-
Michel G, Gianinazzi ME, Vetsch J, Mader L, Lupatsch JE, von der Weid NX, and Rueegg CS
- Subjects
- Adolescent, Age Factors, Child, Continuity of Patient Care standards, Cross-Sectional Studies, Female, General Practitioners, Humans, Male, Medical Oncology, Surveys and Questionnaires, Switzerland, Transition to Adult Care standards, Young Adult, Aftercare standards, Cancer Survivors statistics & numerical data, Oncologists statistics & numerical data, Pediatrics, Physicians statistics & numerical data
- Abstract
Background: Regular follow-up care is essential for childhood cancer survivors, but we know little about physicians' experience with it. We aimed to describe: (1) involvement of Swiss physicians in follow-up care; (2) content of follow-up care provided; (3) problems encountered; and (4) additional resources needed., Materials and Methods: Within this cross-sectional survey we sent adapted questionnaires via professional associations to a sample of medical oncologists (MOs), paediatric oncologists (POs), general practitioners (GPs) and paediatricians (P) in Switzerland. Only oncologists involved in follow-up care were asked to report problems. GPs and Ps not involved in follow-up could indicate why. All physicians were asked about the content of follow-up care provided and additional resources needed., Results: A total of 183 physicians responded (27 MO, 13 PO, 122 GP, 21 P). Involved in follow-up were 81% of MOs, 85% of POs, 39% of GPs and 81% of Ps. Follow-up content differed between oncologists (MO and PO) and generalists (GP and P), with generalists examining or informing less in regard to the former cancer. POs reported more problems than MOs: many POs reported problems with transition of survivors to adult care (91%), and because of financial resources (73%) and time restraints (73%). MOs reported most problems during transition (23%). Not being aware of a survivor was the most common reason for GPs and Ps not participating in follow-up (74%). All groups reported a need for standardised protocols (85-91%) and specialised training (55-73%). GPs (94%) and Ps (100%) additionally desired more support from oncologists., Conclusions: To improve quality and efficiency of follow-up care a national follow-up care model including standardised protocols and guidelines needs to be developed.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.